Locations:

Tag: gene editing

LDL cholesterol particle with a DNA double helix on top of it

November 10, 2025/Heart, Vascular and Thoracic/Preventive Cardiology

CRISPR-Cas9 Gene Editing for Refractory Dyslipidemia Shows Safety and Preliminary Efficacy

First-in-human phase 1 trial induced loss of function in gene that codes for ANGPTL3

February 1, 2024/Cancer/Research

Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

January 30, 2024/Cancer

Gene Therapy Trials Show Positive Results in Sickle Cell Disease and Thalassemia

First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival

October 5, 2021/Bioethics

When the Time Comes: Developing a Complete View of the Risks of Research Studies of Human Germline Genome Editing

Ethical considerations must include the impact on those who would carry children with modified genomes

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

BackPage 1 of 1Next